GlassScriptPhysician profile
Kathryn M Poulos
NPI 1083988323
$2,952.37
in general payments reported to CMS, 2019-2025
27 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $686 · 2023: $836 · 2024: $419 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $541.51 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $302.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $252.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $249.64 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.10 | 2021-2024 | Jardiance, Tradjenta |
| Amgen INC. | $181.23 | 2021-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.49 | 2025 | Caplyta |
| Lilly USA, LLC | $135.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $130.20 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $109.40 | 2021-2023 | |
| Exact Sciences Corporation | $101.08 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $97.68 | 2022-2023 | Hetlioz |
| Lundbeck LLC | $70.12 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $62.13 | 2023-2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $45.73 | 2025 | Xhance, Nuzyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $44.36 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Novo Nordisk INC | $41.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.38 | 2022-2025 | Zoryve |
| Dexcom, INC. | $21.78 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $21.64 | 2023 | Voquezna |
| Phadia US INC. | $19.70 | 2021 | |
| Sk Life Science, INC. | $19.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.90 | 2021 | |
| Shield Therapeutics INC | $16.06 | 2023 | Accrufer |
| Biogen, INC. | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Poulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.